Evaxion Biotech A/S Stock price

Equities

EVAX

US29970R2040

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
3.2 USD +6.67% Intraday chart for Evaxion Biotech A/S +4.92% -53.33%
Sales 2024 * - Sales 2025 * 30.37M Capitalization 24.97M
Net income 2024 * -19M Net income 2025 * 9M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.82 x
P/E ratio 2024 *
-0.84 x
P/E ratio 2025 *
-1.75 x
Employees 63
Yield 2024 *
-
Yield 2025 *
-
Free-Float 82.01%
More Fundamentals * Assessed data
Dynamic Chart
European Equities Traded in the US as American Depositary Receipts Slightly Higher Thursday MT
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading MT
Evaxion Biotech A/S Reports Earnings Results for the Full Year Ended December 31, 2023 CI
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Ease Wednesday MT
Transcript : Evaxion Biotech A/S - Special Call
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Modestly in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Open Week Flat in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Move Higher in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading MT
More news

Latest transcript on Evaxion Biotech A/S

1 day+6.67%
1 week+5.61%
Current month-11.11%
1 month-11.11%
3 months-54.29%
6 months-61.86%
Current year-53.33%
More quotes
1 week
2.90
Extreme 2.9
3.20
1 month
2.82
Extreme 2.8243
3.79
Current year
2.82
Extreme 2.8243
13.61
1 year
2.82
Extreme 2.8243
18.50
3 years
2.82
Extreme 2.8243
250.40
5 years
2.82
Extreme 2.8243
250.40
10 years
2.82
Extreme 2.8243
250.40
More quotes
Managers TitleAgeSince
Founder - 08-08-10
Founder 46 08-08-10
Chief Executive Officer 52 23-08-28
Members of the board TitleAgeSince
Director/Board Member 54 17-12-31
Director/Board Member 66 21-05-24
Chairman 56 17-12-31
More insiders
Date Price Change Volume
24-03-28 3.2 +6.67% 17,197
24-03-27 3 -4.15% 25,627
24-03-26 3.13 +0.97% 9,983
24-03-25 3.1 +1.64% 15,588
24-03-22 3.05 0.00% 14,565

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Evaxion Biotech A/S is a Denmark-based clinical-stage biotechnology company, which specializes in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases. The Company decodes the human immune system to discover and develop immunotherapies to treat cancer and infectious diseases. Based on AI-immunology core technology, Evaxion is developing a pipeline of product candidates. In addition, Evaxion develops portfolio of vaccines to prevent bacterial and viral infections.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
3.2 USD
Average target price
13.67 USD
Spread / Average Target
+327.08%
Consensus
  1. Stock
  2. Equities
  3. Stock Evaxion Biotech A/S - Nasdaq